(Q40884368)

24 September 2017

1 reference

title

Vindesine in the treatment of leukaemia (English)

1 reference

24 September 2017

1 reference

Gökbuget N

1

1 reference

PubMed ID

9389357

24 September 2017

Hoelzer D

series ordinal

2

1 reference

24 September 2017

1 August 1997

1 reference

24 September 2017

1 reference

24 September 2017

26

1 reference

24 September 2017

497-506

1 reference

24 September 2017

5-6

1 reference

Pharmacology, Clinical Efficacy and Adverse Effects of Vindesine Sulfate, A New Vinca Alkaloid

24 September 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Vindesine: a phase II study in childhood malignancies-a report for cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Vindesine in the treatment of refractory hematologic malignancies: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Vindesine a short review of preclinical and first clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Vindesine a review of phase-II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Vindesine and prednisone for remission induction in children with acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Vindesine, prednisone, and daunomycin in acute lymphoblastic leukemia in relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Treatment of relapsed or refractory adult acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Enhanced expression of the multidrug resistance gene in vindesine-resistant human esophageal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Experimental in vivo cross-resistance of vinca alkaloid drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). The Japanese Children's Cancer and Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

A randomised trial of vindesine plus interferon-alpha 2b compared with interferon-alpha 2b or vindesine alone in the treatment of advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse P388 leukemia in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

Preclinical and Clinical Pharmacology of Vinca Alkaloids

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709050886

10.3109/10428199709050886

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9389357